-
E-mail
marklee@hankosci.com
-
Phone
15800598580
-
Address
Kaixin Business Park, No. 1325 Hengnan Road, Minhang District, Shanghai
Shanghai Haokuo Scientific Equipment Co., Ltd
MaxCyte empowers' self arming 'CAR-T therapy: helps break through the immune suppression barrier of solid tumors
Date: 2025-11-24Read: 1
Keywords: domestic clinical cases, high impact factors MaxCyte GTx、 Co transfection case
Recently, Cancer Hospital of the Chinese Academy of Medical Sciences, Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences, School of Medicine of Shanghai University, and Shanghai Cell Therapy Group Co., Ltd. jointly published on Advanced Science (IF: 14.1“Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies”The research paper.
01. Research Background
Malignant mesothelioma is a highly invasive cancer with limited therapeutic efficacy. Although CAR-T therapy is successful in hematological malignancies, it often fails in solid tumors due to immune suppression of the tumor microenvironment, such as the PD-1/PD-L1 pathway.
02. Innovation of this research
Shanghai Cell Therapy Group, in collaboration with multiple institutions, has developed a new type of NAC-T cell:
(1) Targeting MSLN (mesothelioma overexpressed antigen)
(2) Comes with anti-PD-1 nanobody "armor", self-produced and sold, locally blocks immune suppression
03. MaxCyte GTx 助力
(1) Using the MaxCyte electroporation system, piggyBac transposase mRNA, anti MSLN CAR plasmid, and anti-PD-1 nanobody plasmid were co transfected into human peripheral blood derived T cells.
(2) Realize multi gene synchronous non viral transfection to avoid viral vector limitations.
(3) After electroporation, the cell activity is high, meeting the clinical production requirements.
04. What problems should be solved
(1) Breaking through immune suppression - NAC-T releases anti-PD-1 nanobodies locally in the tumor, relieving the immune brake.
(2) Improving the durability of therapeutic effects - in 11 late stage patients:
-Objective relief rate 63.6%
-Disease control rate of 100%
-The median overall survival was 25.6 months
(3) Good safety - no dose limiting toxicity, all CRS are mild to moderate.
05. Clinical significance
This study provides a new approach for solid tumor CAR-T therapy: endowing CAR-T with "self arming" ability through the MaxCyte electroporation platform, achieving local immune regulation, and bringing new hope to refractory tumors such as malignant mesothelioma!
*Reference materials:
Y. Sun, H. Yang, Q. Xu, et al. “ Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.” Adv. Sci. (2025): e08754.
▍Regarding MaxCyte:
MaxCyte was founded in 1999 and is headquartered in Maryland, USA. It is a provider of cell engineering electroporation technology solutions. Utilize its ExPERT ™ The electroporation platform can efficiently and stably achieve engineering processing of large-scale cells, meeting the full stage of cell transfection needs from early research, clinical development to commercial production. It widely serves fields such as antibody protein expression, vaccine development, gene editing, and cell and gene therapy. ——As the general agent of MaxCyte in the southern region of China, Shanghai Haoxuan will provide you with professional solutions and technical support that meet your cell transfection requirements at different stages of research and development, clinical practice, and commercial production.
▍Regarding Shanghai Haokuan:
Shanghai Haokuo Scientific Equipment Co., Ltd. was established in 2019 and is headquartered in Shanghai. It is a professional service provider of laboratory equipment/consumables and analytical instruments. The company is committed to providing high-tech professional equipment and technical consulting services to customers in the fields of biology, medicine, physical property testing, chemical analysis, food, industrial production, and other related fields at home and abroad.